Dr

Farhad Dehkhoda

Email: 

Availability

Dr Farhad Dehkhoda is:
Available for supervision

Search Professor Farhad Dehkhoda’s works on UQ eSpace

10 works between 2013 and 2025
All (10) Journal Article (7) Book Chapter (1) Conference Publication (1) Other Outputs (1)

1 - 10 of 10 works

2025

Other Outputs

Molecular Cell Dataset "Determination of the mechanism for reversed dopamine D2 receptor cellular output enabled by constitutive ghrelin receptor activity."

Furness, Sebastian, Ambaw, Desye Misganaw, Mutunduwe, Keith, Dehkhoda, Farhad and Piper, Noah (2025). Molecular Cell Dataset "Determination of the mechanism for reversed dopamine D2 receptor cellular output enabled by constitutive ghrelin receptor activity.". The University of Queensland. (Dataset) doi: 10.48610/005d1e7

Molecular Cell Dataset "Determination of the mechanism for reversed dopamine D2 receptor cellular output enabled by constitutive ghrelin receptor activity."

2024

Journal Article

The ATM Ser49Cys variant effects ATM function as a regulator of oncogene-induced senescence

Atkinson, Caroline, McInerney-Leo, Aideen, Proctor, Martina, Lanagan, Catherine, Stevenson, Alexander, Dehkhoda, Farhad, Caole, Mary, Maas, Ellie, Ainger, Stephen, Pritchard, Antonia, Johansson, Peter, Leo, Paul, Hayward, Nicholas, Sturm, Richard, Duncan, Emma and Gabrielli, Brian (2024). The ATM Ser49Cys variant effects ATM function as a regulator of oncogene-induced senescence. International Journal of Molecular Sciences, 25 (3) 1664, 1-12. doi: 10.3390/ijms25031664

The ATM Ser49Cys variant effects ATM function as a regulator of oncogene-induced senescence

2023

Journal Article

Tyrosine kinases compete for growth hormone receptor binding and regulate receptor mobility and degradation

Chhabra, Yash, Seiffert, Pernille, Gormal, Rachel S., Vullings, Manon, Lee, Christine Mei Mei, Wallis, Tristan P., Dehkhoda, Farhad, Indrakumar, Sowmya, Jacobsen, Nina L., Lindorff-Larsen, Kresten, Durisic, Nela, Waters, Michael J., Meunier, Frederic A., Kragelund, Birthe B. and Brooks, Andrew J. (2023). Tyrosine kinases compete for growth hormone receptor binding and regulate receptor mobility and degradation. Cell Reports, 42 (5) 112490, 112490. doi: 10.1016/j.celrep.2023.112490

Tyrosine kinases compete for growth hormone receptor binding and regulate receptor mobility and degradation

2023

Conference Publication

Modulation of dopamine's effect at dopamine 2 receptors (D2R) mediated by association with the ghrelin receptor, GHSR

Furness, John, Dehkhoda, Farhad, Whitfield, Emily, Fothergill, Linda, Misgenaw, Desye, Ringuet, Mitchell and Furness, Sebastian (2023). Modulation of dopamine's effect at dopamine 2 receptors (D2R) mediated by association with the ghrelin receptor, GHSR. American Physiology Summit 2023, Long Beach, CA, United States, 20-23 April 2023. Rockville, MD, United States: American Physiological Society. doi: 10.1152/physiol.2023.38.s1.5731818

Modulation of dopamine's effect at dopamine 2 receptors (D2R) mediated by association with the ghrelin receptor, GHSR

2023

Journal Article

The SOCS1 KIR and SH2 domain are both required for suppression of cytokine signaling in vivo

Doggett, Karen, Keating, Narelle, Dehkhoda, Farhad, Bidgood, Grace M., Meza Guzman, Lizeth G., Leong, Evelyn, Kueh, Andrew, Nicola, Nicos A., Kershaw, Nadia J., Babon, Jeffrey J., Alexander, Warren S. and Nicholson, Sandra E. (2023). The SOCS1 KIR and SH2 domain are both required for suppression of cytokine signaling in vivo. Cytokine, 165 156167, 1-8. doi: 10.1016/j.cyto.2023.156167

The SOCS1 KIR and SH2 domain are both required for suppression of cytokine signaling in vivo

2022

Journal Article

Optimization of phosphotyrosine peptides that target the SH2 domain of SOCS1 and block substrate ubiquitination

Chen, Hao, Wu, Yuntong, Li, Kunlun, Currie, Iain, Keating, Narelle, Dehkhoda, Farhad, Grohmann, Christoph, Babon, Jeffrey J., Nicholson, Sandra E. and Sleebs, Brad E. (2022). Optimization of phosphotyrosine peptides that target the SH2 domain of SOCS1 and block substrate ubiquitination. ACS Chemical Biology, 17 (2), 449-462. doi: 10.1021/acschembio.1c00884

Optimization of phosphotyrosine peptides that target the SH2 domain of SOCS1 and block substrate ubiquitination

2021

Journal Article

Discovery of an exosite on the SOCS2-SH2 domain that enhances SH2 binding to phosphorylated ligands

Linossi, Edmond M., Li, Kunlun, Veggiani, Gianluca, Tan, Cyrus, Dehkhoda, Farhad, Hockings, Colin, Calleja, Dale J., Keating, Narelle, Feltham, Rebecca, Brooks, Andrew J., Li, Shawn S., Sidhu, Sachdev S., Babon, Jeffrey J., Kershaw, Nadia J. and Nicholson, Sandra E. (2021). Discovery of an exosite on the SOCS2-SH2 domain that enhances SH2 binding to phosphorylated ligands. Nature Communications, 12 (1) 7032, 7032. doi: 10.1038/s41467-021-26983-5

Discovery of an exosite on the SOCS2-SH2 domain that enhances SH2 binding to phosphorylated ligands

2018

Journal Article

The growth hormone receptor: mechanism of receptor activation, cell signaling, and physiological aspects

Dehkhoda, Farhad , Lee, Christine M. M. , Medina, Johan and Brooks, Andrew J. (2018). The growth hormone receptor: mechanism of receptor activation, cell signaling, and physiological aspects. Frontiers in Endocrinology, 9 (35) 35, 35. doi: 10.3389/fendo.2018.00035

The growth hormone receptor: mechanism of receptor activation, cell signaling, and physiological aspects

2018

Book Chapter

Cytokine receptors

Brooks, Andrew J., Dehkhoda, Farhad and Kragelund, Birthe (2018). Cytokine receptors. Endocrinology: principles of endocrinology and hormone action. (pp. 157-185) edited by Antonino Belfiore and Derek LeRoith. Amsterdam, The Netherlands: Springer. doi: 10.1007/978-3-319-44675-2_8

Cytokine receptors

2013

Journal Article

The N550K/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib, and ponatinib ATP-competitive inhibitors

Byron, Sara A., Chen, Huaibin, Wortmann, Andreas, Loch, David, Gartside, Michael G., Dehkhoda, Farhad, Blais, Steven P., Neubert, Thomas A., Mohammadi, Moosa and Pollock, Pamela M. (2013). The N550K/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib, and ponatinib ATP-competitive inhibitors. NeoPlasia, 15 (8), 975-988. doi: 10.1593/neo.121106

The N550K/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib, and ponatinib ATP-competitive inhibitors

Availability

Dr Farhad Dehkhoda is:
Available for supervision

Before you email them, read our advice on how to contact a supervisor.

Supervision history

Current supervision

Completed supervision

Enquiries

For media enquiries about Dr Farhad Dehkhoda's areas of expertise, story ideas and help finding experts, contact our Media team:

communications@uq.edu.au